A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
Introduction Shorter courses of antimicrobials have been shown to be non-inferior to longer, “traditional” duration of therapies, including for some severe healthcare-associated infections, with a few exceptions. However, evidence is lacking regarding shorter regimes against severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB), which are often caused by distinct strains and commonly treated with second-line antimicrobials. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we aim to assess the non-inferiority of 7-day versus 14-day antimicrobial therapy in critically ill patients with severe infections caused by MDR-GNB. Methods This is a randomized, multicenter, open-label, parallel controlled trial to assess the non-inferiority of 7-day versus 14-day of adequate antimicrobial therapy for intensive care unit (ICU)-acquired severe infections by MDR-GNB. Adult patients with severe infections by MDR-GNB initiated after 48 h of ICU admission are screened for eligibility. Patients are eligible if they proved to be hemodynamically stable and without fever for at least 48 h on the 7th day of adequate antimicrobial therapy. After consenting, patients are 1:1 randomized to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14th (± 1) days. Planned Outcomes The primary outcome is treatment failure, defined as death or relapse of infection within 28 days after randomization. Non-inferiority will be achieved if the upper edge of the two-tailed 95% confidence interval of the difference between the clinical failure rate in the 7-day and the 14-day group is not higher than 10%. Conclusion The OPTIMISE trial is the first randomized controlled trial specifically designed to assess the duration of antimicrobial therapy in patients with severe infections by MDR-GNB. Trial Registration ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE)..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Infectious diseases and therapy - 13(2023), 1 vom: 16. Dez., Seite 237-250 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Arns, Beatriz [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Antimicrobial resistance |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1007/s40121-023-00897-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR054592801 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR054592801 | ||
003 | DE-627 | ||
005 | 20240131064714.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240131s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40121-023-00897-9 |2 doi | |
035 | |a (DE-627)SPR054592801 | ||
035 | |a (SPR)s40121-023-00897-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Arns, Beatriz |e verfasserin |0 (orcid)0000-0002-4464-9763 |4 aut | |
245 | 1 | 2 | |a A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Introduction Shorter courses of antimicrobials have been shown to be non-inferior to longer, “traditional” duration of therapies, including for some severe healthcare-associated infections, with a few exceptions. However, evidence is lacking regarding shorter regimes against severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB), which are often caused by distinct strains and commonly treated with second-line antimicrobials. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we aim to assess the non-inferiority of 7-day versus 14-day antimicrobial therapy in critically ill patients with severe infections caused by MDR-GNB. Methods This is a randomized, multicenter, open-label, parallel controlled trial to assess the non-inferiority of 7-day versus 14-day of adequate antimicrobial therapy for intensive care unit (ICU)-acquired severe infections by MDR-GNB. Adult patients with severe infections by MDR-GNB initiated after 48 h of ICU admission are screened for eligibility. Patients are eligible if they proved to be hemodynamically stable and without fever for at least 48 h on the 7th day of adequate antimicrobial therapy. After consenting, patients are 1:1 randomized to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14th (± 1) days. Planned Outcomes The primary outcome is treatment failure, defined as death or relapse of infection within 28 days after randomization. Non-inferiority will be achieved if the upper edge of the two-tailed 95% confidence interval of the difference between the clinical failure rate in the 7-day and the 14-day group is not higher than 10%. Conclusion The OPTIMISE trial is the first randomized controlled trial specifically designed to assess the duration of antimicrobial therapy in patients with severe infections by MDR-GNB. Trial Registration ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE). | ||
650 | 4 | |a Gram-negative bacilli |7 (dpeaa)DE-He213 | |
650 | 4 | |a Antimicrobial therapy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Antimicrobial resistance |7 (dpeaa)DE-He213 | |
650 | 4 | |a Enterobacterales |7 (dpeaa)DE-He213 | |
700 | 1 | |a Horvath, Jaqueline Driemeyer C. |0 (orcid)0000-0001-8440-6590 |4 aut | |
700 | 1 | |a Rech, Gabriela Soares |0 (orcid)0000-0001-5122-8820 |4 aut | |
700 | 1 | |a Sesin, Guilhermo Prates |0 (orcid)0000-0002-8607-3467 |4 aut | |
700 | 1 | |a Agani, Crepin Aziz Jose Oluwafoumi |0 (orcid)0000-0001-5987-1351 |4 aut | |
700 | 1 | |a da Rosa, Bruna Silveira |0 (orcid)0009-0008-7547-1815 |4 aut | |
700 | 1 | |a dos Santos, Tiago Marcon |0 (orcid)0000-0002-7328-6092 |4 aut | |
700 | 1 | |a Brochier, Liliane Spencer Bittencourt |0 (orcid)0000-0003-0778-5018 |4 aut | |
700 | 1 | |a Cavalcanti, Alexandre Biasi |0 (orcid)0000-0003-2798-6263 |4 aut | |
700 | 1 | |a Tomazini, Bruno Martins |0 (orcid)0000-0001-6763-6132 |4 aut | |
700 | 1 | |a Pereira, Adriano Jose |0 (orcid)0000-0002-3528-3800 |4 aut | |
700 | 1 | |a Veiga, Viviane Cordeiro |0 (orcid)0000-0002-0287-3601 |4 aut | |
700 | 1 | |a Nascimento, Giovana Marssola |0 (orcid)0009-0005-5071-3775 |4 aut | |
700 | 1 | |a Kalil, Andre C. |0 (orcid)0000-0002-6489-6294 |4 aut | |
700 | 1 | |a Zavascki, Alexandre P. |0 (orcid)0000-0001-5331-4837 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d Heidelberg : Springer, 2012 |g 13(2023), 1 vom: 16. Dez., Seite 237-250 |w (DE-627)SPR032878133 |w (DE-600)2701611-0 |x 2193-6382 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:16 |g month:12 |g pages:237-250 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40121-023-00897-9 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 13 |j 2023 |e 1 |b 16 |c 12 |h 237-250 |